Companies
Glaxo and Synta drug gets orphan status from FDA
By William Dove
Font Scale: 
Posted 28 January 2008 @ 02:15 pm GMT
Pharmaceutical company GlaxoSmithKline PLC and the American based Synta Pharmaceuticals have said that the US Food and Drug Administration (FDA) has granted the drug Elesclomol, orphan drug status. Elesclomol is a medicine meant to treat metastatic melanoma.
Article Tags 
administration and drug elesclomol food glaxosmithkline pharmaceuticals synta
Asian stocks rise on relief over U.S. outlookFollowing the decision by the FDA, Elesclomol can now begin an accelerated clinical trials programme as there are few patients with the disease and there are no adequate treatments available for metastatic melanoma
GlaxoSmithKline signed a co-development deal with Synta in October of last year to bring Elesclomol to the market. Synta can potentially earn $1 billion in development bonuses if all milestones are met, according to Thomson Financial.
This article is copyrighted by the International Business Times.
Most Popular Stories
- 1 RBS gets Chinese approval for Suzhou stake
- 2 June retail sales fall less than expected
- 3 Auction-rate buybacks add to worries
- 4 Pound hits near 12-year low
- 5 Miliband urges coalition against Russia in Georgia
- 6 Mortgage approvals hold near record low in July
- 7 Kazakhmys earnings down as bad weather hits
- 1 Could $100 oil turn dumps into plastic mines?
- 2 Era of exclusive video game deals ending
- 3 Auction-rate buybacks add to worries
- 4 Audit shows China mismanaged 3.7 bln pounds
- 5 Gold firms near 2-week highs on oil, physicals support
- 6 Investors lift stocks, keep exposure thin
- 7 Councils seek powers to offer mortgages
|
Top Stories on Companies
- 1 RBS gets Chinese approval for Suzhou stake
- 2 Regus profit soars in first half
- 3 PartyGaming CEO targets DoJ resolution this year
- 4 Zoom Airlines grounds planes and files for bankruptcy
- 5 B&B sinks to first-half loss
- 6 Hunting's profit rises 11 pct on high oil prices
- 7 IMI posts profit and sees more progress
|
|
